Amneal Pharmaceuticals (AMRX) Stock: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.01
0.14 (0.83%)
▲
5d:
-4.81%
30d:
-3.68%
90d:
+4.1%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.52
Based on 9.6% avg growth
INTRINSIC VALUE TODAY
$15.23
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $17.01, which is considered oversold relative to its 30-day fair value range of $17.45 to $18.30. The stock's valuation (Forward PE: 14.7) is in line with its historical norms (13.4). At these levels, the market is pricing in 3.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is currently testing key support at $16.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AMRX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+23.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is currently testing key support at $16.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AMRX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+23.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.45 -
$18.30
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding AMRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.5% below Wall St target ($21.00)
- NEUTRAL: Market pricing in 3.1% annual earnings growth - fairly valued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.45 -
$18.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$16.73
Resistance Level
$18.32
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.65
Wall Street Target
$21.00
(+23.5%)
Revenue Growth (YoY)
9.9%
Earnings Growth (YoY)
157.1%
Profit Margin
5.1%
Valuation Premium vs History
+3.1% premium
PE vs Historical
14.7 vs 13.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.1%
(market-implied from PE analysis)
1-Year Target
$17.54
(+3%)
2-Year Target
$18.08
(+6%)
3-Year Target
$18.64
(+10%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$17.05
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 15.2%)
$35.78
(+110%)
Base:
(SPY PE: 14.7, Growth: 15.2%)
$25.99
(+53%)
Bear:
(PE: 12.5, Growth: 15.2%)
$22.09
(+30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 35.89 | Current EPS (TTM): $0.47
Bull Case
$37.11
(+118%)
Analyst growth 100.0%, PE expands to 39.5
Base Case
$33.74
(+98%)
Market implied 100.0%, PE stable at 35.9
Bear Case
$11.47
(-33%)
Severe decline -20.0%, PE contracts to 30.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 12:05 PM ET
Data refreshes hourly during market hours. Next update: 1:05 PM
Data refreshes hourly during market hours. Next update: 1:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
